Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for symptomatic uterine fibroids
IRCT20240122060769N1Phase 3Recruiting
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) comparing Metformin with Placebo (2 arms). Primary endpoints: Change in uterine dimensions, Change in endometrial thickness and 5 more. Started Nov 2025; status: recruiting.
02
Drugs
metformin
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20240122060769N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240122060769N1.